PT-141 (Bremelanotide) is a synthetic cyclic peptide fragment derived from Melanotan II that functions as a selective melanocortin receptor agonist. For domestic investigators seeking high-purity PT-141 amino research materials in the USA, establishing lot-specific verification via RP-HPLC and mass spectrometry is essential for reproducible preclinical experimentation.
PT-141 (Bremelanotide) is a synthetic cyclic peptide fragment derived from Melanotan II that functions as a selective melanocortin receptor agonist. For domestic investigators seeking high-purity PT-141 amino research materials in the USA, establishing lot-specific verification via RP-HPLC and mass spectrometry is essential for reproducible preclinical experimentation.
In modern biochemical literature, the term 'PT-141 amino USA' refers to American-manufactured Bremelanotide synthesized under strict laboratory controls for in vitro and preclinical research applications. PT-141 is a synthetic peptide derivative of alpha-melanocyte-stimulating hormone (α-MSH) that selectively activates central melanocortin receptors (primarily MC3R and MC4R). United States research institutions require domestic sourcing to ensure rapid climate-controlled transport, full lot traceability, and independent verification through ISO 17025 accredited laboratories.
Researchers evaluating the PT-141 research compound rely on USA-based manufacturers to avoid international cold-chain degradation and unverified chemical purities. Obtaining verified amino acid sequences from certified domestic suppliers guarantees that empirical observations in central signaling assays stem from unadulterated, endotoxin-tested peptide formulations.
PT-141, chemically known as Bremelanotide, possesses the molecular formula C50H68N14O10 and a molecular mass of 1024.2 g/mol. Structurally, it is a cyclic heptapeptide analog of α-MSH with the primary amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The structural modification includes a side-chain to side-chain cyclization between aspartic acid and lysine, which imparts enhanced metabolic stability compared to linear endogenous melanocortin peptides.
Unlike its parent compound Melanotan II, PT-141 lacks the terminal amide modification and possesses distinct binding affinities. This cyclized lactam structure resists enzymatic cleavage by ubiquitous carboxypeptidases and endopeptidases in experimental media, allowing researchers to evaluate sustained receptor binding kinetics in both cell culture assays and animal models.
When analyzing raw materials within the catalog of research peptides, verifying the precise sequence and cyclic integrity is critical. Incomplete cyclization or residual linear peptide fragments can fundamentally alter receptor selectivity, leading to aberrant binding data in downstream quantitative assays.
The primary mechanism of action for PT-141 involves potent agonist activity at central melanocortin receptors, specifically sub-types MC3R and MC4R. While endogenous α-MSH activates MC1R, MC3R, MC4R, and MC5R non-selectively, PT-141 exhibits a dominant affinity for central nervous system receptors located within the hypothalamus and preoptic area.
In vitro functional assays demonstrate that binding of PT-141 to MC4R stimulates G-protein coupled receptor (GPCR) intracellular signaling pathways. This binding activates adenylyl cyclase, driving an elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. Unlike peripheral vasoactive compounds that alter hemodynamics directly through nitric oxide pathways, PT-141 exerts its physiological responses via neurochemical signaling cascades in central neural circuits.
Understanding these central pathways is vital when conducting studies on melanocortin system signaling. Research shows that MC4R activation in the paraventricular nucleus (PVN) and medial preoptic area (mPOA) modulates downstream dopaminergic pathways, influencing motivation, appetitive behavior, and autonomic responses in preclinical models.
Preclinical investigation into PT-141 has centered predominantly on its capacity to modulate central nervous system responses linked to physiological pathways. Rodent assays demonstrate that central administration of PT-141 stimulates appetitive and consummatory behaviors independent of peripheral vascular modulation.
In animal models, administration of PT-141 into the lateral ventricles or systemic circulation leads to quantifiable activation of c-Fos expression within the hypothalamus. This neural activation correlates directly with enhanced appetitive responses, displaying a distinct dose-dependent curve. In female rodent models, researchers observe an increase in lordosis behavior following central MC4R stimulation, illustrating the compound's regulatory influence over central neuroendocrine circuits.
Additionally, non-human primate studies have evaluated PT-141 to delineate central melanocortin actions from peripheral vascular mechanisms. Because PT-141 bypasses direct vascular smooth muscle ion channels, it serves as a valuable control compound for isolating central neurochemical activation from systemic hemodynamic alterations.
Within neurochemical research, investigators frequently compare PT-141 against other central signaling peptides to isolate specific receptor-mediated responses. Below is a comparative overview of three prominent compounds evaluated in behavioral and neuroendocrine literature:
While Melanotan II acts as a non-selective melanocortin agonist with significant affinity for MC1R (driving peripheral melanogenesis), PT-141 exhibits reduced MC1R activity, making it a more selective probe for central MC3R/MC4R signaling pathways. Conversely, Oxytocin operates through distinct nonapeptide oxytocinergic GPCR pathways involved in social bonding and neuropeptide modulation rather than melanocortin receptors. Evaluating PT-141 alongside these comparative agents allows research teams to map specific central pathways without confounding cross-receptor activity.
To preserve the structural integrity of PT-141 amino peptides during laboratory experimentation, strict handling and reconstitution standards must be maintained. Lyophilized PT-141 should be stored at -20°C or -80°C in a desiccated environment to prevent moisture absorption and hydrolysis.
When preparing solutions for in vitro or ex vivo assays, researchers should reconstitute the lyophilized powder using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4). Solvents should be introduced along the glass vial wall, followed by gentle swirling. Mechanical agitation, such as vigorous shaking or vortexing, must be avoided to prevent shear stress and peptide aggregation.
For detailed laboratory execution, consult our technical guide on peptide reconstitution guidelines. Once reconstituted, liquid aliquots should be used immediately or stored at 4°C for short-term use (up to 7 days). For long-term analytical protocols, aliquots should be frozen at -80°C to avoid repeated freeze-thaw cycles that can induce peptide degradation.
The scientific validity of preclinical research relies entirely on the purity and chemical identity of the test compounds. Sourcing PT-141 amino research peptides from reputable USA suppliers ensures rigorous compliance with analytical standards through comprehensive lot-specific documentation.
Every production lot must undergo Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity, which should consistently exceed 98.0%. In tandem, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weight (1024.2 Da), verifying the absence of truncated sequences, deletion peptides, or synthesis byproducts.
Furthermore, cell culture and animal model experiments require strict monitoring of bacterial endotoxins. Utilizing Limulus Amebocyte Lysate (LAL) testing, top-tier suppliers ensure endotoxin levels remain below 0.01 EU/mg. Accessing verified analytical certificates via the PX1 Research hub provides laboratory personnel with the empirical transparency required for high-impact publication.
PX1 Research serves as a premier USA-based supplier of analytical-grade research compounds, adhering to stringent quality management protocols. Manufactured in state-of-the-art domestic facilities operating under GMP-compliant guidelines, all PX1 peptides undergo independent testing in ISO 17025 accredited laboratories.
Domestic fulfillment centers located in California and Arizona enable same-day dispatch (Monday through Friday), mitigating transport temperature variations and avoiding international customs delays. Every vial of PT-141 features lot-tracked QR coding linking directly to authentic RP-HPLC chromatograms and mass spectra.
Academic institutions, biotechnology firms, and contract research organizations (CROs) requiring larger volume quantities can establish institutional accounts through the PX1 wholesale portal. PX1 guarantees consistent batch-to-batch purity, transparent documentation, and reliable domestic supply chains to support rigorous scientific inquiry.
What is the precise chemical name and molecular weight of PT-141?
PT-141 is chemically known as Bremelanotide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH). It has a molecular weight of 1024.2 g/mol and a molecular formula of C50H68N14O10.
What receptor sub-types does PT-141 target in preclinical research?
PT-141 acts as a central melanocortin receptor agonist, exhibiting high binding affinity for MC3R and MC4R sub-types located within the central nervous system.
Why is USA domestic sourcing preferred for PT-141 amino research compounds?
Domestic USA sourcing ensures rapid climate-controlled shipping (preventing peptide thermal degradation), strict adherence to GMP/ISO 17025 testing standards, verified low endotoxin levels, and immediate access to lot-specific analytical documentation.
How should PT-141 be reconstituted for laboratory protocols?
Lyophilized PT-141 should be reconstituted using sterile bacteriostatic water or sterile PBS (pH 7.4). Solvents should be added slowly along the vial container wall, followed by gentle rotation. Avoid high-shear mechanical vortexing.
What analytical tests verify the purity of PX1 Research PT-141?
PX1 Research verifies PT-141 purity through Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for chemical purity (≥98%), Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence identity confirmation, and LAL assays for endotoxin quantification.
How does PT-141 differ structurally from Melanotan II?
While derived from Melanotan II, PT-141 lacks the C-terminal amide group and exhibits a modified cyclic structure that reduces MC1R activity while maintaining potent central MC3R and MC4R agonism.
What are the recommended long-term storage conditions for lyophilized PT-141?
Lyophilized PT-141 should be stored in a desiccated container at -20°C or -80°C. Protect the peptide from light exposure to maintain long-term chemical stability.
Are PX1 Research compounds intended for human use or clinical therapy?
No. All products supplied by PX1 Research, including PT-141, are strictly for laboratory research use only (RUO), in vitro assays, and preclinical animal models. They are not for human consumption, medical, therapeutic, or diagnostic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.